NCT02073279 · Interventional trial
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Overall registry status Completed
Phase 3
Conditions NMO Spectrum Disorder (NMOSD), Neuromyelitis Optica (NMO)
Delaware Valley sites
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory